4//SEC Filing
Beers David C 4
Accession 0001209191-21-047517
CIK 0001752828other
Filed
Jul 19, 8:00 PM ET
Accepted
Jul 20, 9:22 PM ET
Size
8.8 KB
Accession
0001209191-21-047517
Insider Transaction Report
Form 4
Celularity IncCELU
Beers David C
Chief Financial Officer
Transactions
- Award
Stock Option (Right to Buy)
2021-07-16+76,859→ 76,859 totalExercise: $10.21Exp: 2031-07-16→ Class A Common Stock (76,859 underlying) - Award
Stock Option (Right to Buy)
2021-07-16+538,015→ 538,015 totalExercise: $3.70Exp: 2031-07-16→ Class A Common Stock (538,015 underlying)
Footnotes (3)
- [F1]This option shall vest and become exercisable over a period of four years from the Vesting Start Date, January 31, 2020, with 25% vesting on the one year anniversary of the Vesting Start Date, and the remainder vesting over a period of 36 months thereafter, subject to the Reporting Person's continuous service with the Issuer on each such date.
- [F2]Pursuant to the Merger Agreement and Plan of Merger and Reorganization, dated January 8, 2021 (the "Business Combination Agreement"), by and among GX Acquisition Corp. ("GX"), Alpha First Merger Sub Corp., Celularity LLC and Celularity Inc. ("Legacy Celularity"), each security to purchase shares of Legacy Celularity common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a 1-to-0.768594024295126 conversion ratio. Upon consummation of the business combination, GX changed its name to "Celularity Inc."
- [F3]This option is fully vested and exercisable.
Documents
Issuer
Celularity Inc
CIK 0001752828
Entity typeother
Related Parties
1- filerCIK 0001869583
Filing Metadata
- Form type
- 4
- Filed
- Jul 19, 8:00 PM ET
- Accepted
- Jul 20, 9:22 PM ET
- Size
- 8.8 KB